MassChallenge Texas named its top three startups of its inaugural Houston cohort and the Houston Angel Network made an unexpected investment. Courtesy of MassChallenge Texas

A new-to-Houston global accelerator program just concluded its inaugural cohort, naming three top startups and providing a platform for an unexpected prize — an investment.

MassChallenge Texas didn't originally intend to have monetary prizes for this first program, however, thanks to Houston Angel Network, one lucky startup is walking away from the program $40,000 richer.

HAN, one of Houston's oldest and most active group of angel investors, saw pitch decks from most of the companies in the cohort and then invited seven companies to pitch: Ask DOSS, Celise, DoBrain, NeuroRescue, Noleus Technologies, Sensytec, and Swoovy.

At the September 5 startup showcase event, HAN named Houston-based Sensytec as the winner of the $40,000 investment prize.

The night's other big winners were MassChallenge's top three startups, program: NeuroRescue, Noleus Technologies, and Sensytec, which were selected from the top six startups that were announced a couple weeks in advance.

HAN engaged with the MassChallenge group in a few ways — like mentorship or presenting — but managing director Stephanie Campbell says she knew she wanted to discuss investment opportunities from the very beginning.

"I just think it's really important that when a new group like MassChallenge or any other accelerator come into town that we find ways to fold them into our community and help them be successful," she tells InnovationMap.

All of this year's cohort will receive 18 months of free coworking space — six months at MassChallenge, six months at The Cannon, and six months at Station Houston — and the top three startups will receive automatic entry into another MassChallenge cohort. Because no one won a cash prize from MassChallenge directly, all of the startups are eligible to reapply for another program.

"We wanted to make sure that the companies that went through the shortened version of the program this year have the ability to apply next year to any other program," MassChallenge Texas' Houston managing director, Jon Nordby, says.

Next time around, MassChallenge Texas will likely have a longer program with money on the table. That money would be provided by the organization's corporate partners. The city of Houston has put forth $2.5 million to be dealt out over five years, and Houston-based Reliant Energy has become a central partner to MassChallenge.

"We believe in supporting organizations that are pushing the boundaries and really making an impact in the community as well as the economy and the industry," says Elizabeth Killinger, president at NRG Retail and Reliant.

Killinger says next year she expects Reliant to be just as if not more involved with the process. Campbell too says HAN is interested in continuing its work with MassChallenge, and even sees it setting an example for other angel investors to get involved too.

"We're just planting the seed for the next cohort," Campbell says.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Nominations are now open for the 2025 Houston Innovation Awards

Calling All Innovators

Calling all Houston innovators: The Houston Innovation Awards return this fall to celebrate the best and brightest in the Houston innovation ecosystem right now.

Presented by InnovationMap, the fifth annual Houston Innovation Awards will take place November 5 at TMC Helix Park.

The awards program will honor the top startups and innovators in Houston across 10 categories, and we're asking you to nominate the most deserving Houston innovators and innovative companies today.

This year's categories are:

  • Minority-founded Business, honoring an innovative startup founded or co-founded by BIPOC or LGBTQ+ representation.
  • Female-founded Business, honoring an innovative startup founded or co-founded by a woman.
  • Energy Transition Business, honoring an innovative startup providing a solution within renewables, climatetech, clean energy, alternative materials, circular economy, and beyond.
  • Health Tech Business, honoring an innovative startup within the health and medical technology sectors.
  • Deep Tech Business, honoring an innovative startup providing technology solutions based on substantial scientific or engineering challenges, including those in the AI, robotics, and space sectors.
  • Startup of the Year (People's Choice), honoring a startup celebrating a recent milestone or success. The winner will be selected by the community via an interactive voting experience.
  • Scaleup of the Year, honoring an innovative later-stage startup that's recently reached a significant milestone in company growth.
  • Incubator/Accelerator of the Year, honoring a local incubator or accelerator that is championing and fueling the growth of Houston startups.
  • Mentor of the Year, honoring an individual who dedicates their time and expertise to guide and support budding entrepreneurs.
  • Trailblazer, honoring an innovator who's made a lasting impact on the Houston innovation community.

Nominations may be made on behalf of yourself, your organization, and other leaders in the local innovation scene. The nomination period closes on August 31, so don't delay — nominate today at this link, or fill out the embedded form below.

Our panel of esteemed judges will review the nominations, and determine the finalists and winners. Finalists will be unveiled on September 30, and the 2025 Houston Innovation Awards winners will be announced live at our event on November 5.

Tickets will go on sale this fall. Stay tuned for that announcement, as well as more fanfare leading up to the 2025 Houston Innovation Awards.

Nominate now:

Interested in Innovation Awards sponsorship opportunities? Please contact sales@innovationmap.com.

MD Anderson launches $10M collaboration to advance personalized cancer treatment tech

fighting cancer

The University of Texas MD Anderson Cancer Center and Japan’s TOPPAN Holdings Inc. have announced a strategic collaboration to co-develop TOPPAN Holdings’ 3D cell culture, or organoid, technology known as invivoid.

The technology will be used as a tool for personalized cancer treatments and drug screening efforts, according to a release from MD Anderson. TOPPAN has committed $10 million over five years to advance the joint research activities.

“The strategic alliance with MD Anderson paves a promising path toward personalized cancer medicine," Hiroshi Asada, head of the Business Innovation Center at TOPPAN Holdings, said in a news release.

Invivoid is capable of establishing organoid models directly from patient biopsies or other tissues in a way that is faster and more efficient. Researchers may be able to test a variety of potential treatments in the laboratory to understand which approach may work best for the patient, if validated clinically.

“Organoids allow us to model the three-dimensional complexity of human cancers in the lab, thus allowing us to engineer a powerful translational engine—one that could not only predict how patients will respond to therapy before treatment begins but also could help to reimagine how we discover and validate next-generation therapies," Dr. Donna Hansel, division head of pathology and laboratory medicine at MD Anderson, added in the news release. “Through this collaboration, we hope to make meaningful progress in modeling cancer biology for therapeutic innovation.”

The collaboration will build upon preclinical research previously conducted by MD Anderson and TOPPAN. The organizations will work collaboratively to obtain College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) certifications for the technology, which demonstrate a commitment to high-quality patient care. Once the certifications are obtained, they plan to conduct observational clinical studies and then prospective clinical studies.

“We believe our proprietary invivoid 3D cell culture technology, by enabling the rapid establishment of organoid models directly from patient biopsies, has strong potential to help identify more effective treatment options and reduce the likelihood of unnecessary therapies,” Asada added in the release. “Through collaboration on CAP/CLIA certification and clinical validation, we aim to bring this innovation closer to real-world patient care and contribute meaningfully to the advancement of cancer medicine."